Search research articles
Contact Us
Filters
Showing results (111-120 of 127) with videos related to
Page
of 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 21, 2010
Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer
Song Yao, William E Barlow, Kathy S Albain, et al.
Journal of the National Cancer Institute
|
March 8, 2012
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial
Meredith M Regan, Brian Leyland-Jones, Mark Bouzyk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 13, 2009
Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial
Ji-Yeob Choi, William E Barlow, Kathy S Albain, et al.
Journal of Medicinal Chemistry
|
April 8, 2025
Correction to "Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer"
Ranjan Kumar Acharyya, Rohan Kalyan Rej, Biao Hu, et al.
Breast Cancer Research and Treatment
|
March 24, 2010
Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer
Song Yao, William E Barlow, Kathy S Albain, et al.
Journal of Medicinal Chemistry
|
November 1, 2024
Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer
Ranjan Kumar Acharyya, Rohan Kalyan Rej, Biao Hu, et al.
Pharmacogenomics
|
August 24, 2023
Effects of <i>CYP3A4</i> and <i>CYP2C9</i> genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226
Delaney V Rutherford, Sarah Medley, Nicholas C Henderson, et al.
Breast Cancer Research and Treatment
|
November 23, 2015
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer
Brian Leyland-Jones, Kathryn P Gray, Mark Abramovitz, et al.
Breast Cancer Research and Treatment
|
November 23, 2006
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
Matthew P Goetz, Stacey K Knox, Vera J Suman, et al.
Journal of Medicinal Chemistry
|
November 25, 2024
Discovery of ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα)
Rohan Kalyan Rej, Biao Hu, Zhixiang Chen, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 127) with videos related to
Sort By:
Page
of 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 21, 2010
Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer
Song Yao, William E Barlow, Kathy S Albain, et al.
Journal of the National Cancer Institute
|
March 8, 2012
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial
Meredith M Regan, Brian Leyland-Jones, Mark Bouzyk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 13, 2009
Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial
Ji-Yeob Choi, William E Barlow, Kathy S Albain, et al.
Journal of Medicinal Chemistry
|
April 8, 2025
Correction to "Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer"
Ranjan Kumar Acharyya, Rohan Kalyan Rej, Biao Hu, et al.
Breast Cancer Research and Treatment
|
March 24, 2010
Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer
Song Yao, William E Barlow, Kathy S Albain, et al.
Journal of Medicinal Chemistry
|
November 1, 2024
Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer
Ranjan Kumar Acharyya, Rohan Kalyan Rej, Biao Hu, et al.
Pharmacogenomics
|
August 24, 2023
Effects of <i>CYP3A4</i> and <i>CYP2C9</i> genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226
Delaney V Rutherford, Sarah Medley, Nicholas C Henderson, et al.
Breast Cancer Research and Treatment
|
November 23, 2015
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer
Brian Leyland-Jones, Kathryn P Gray, Mark Abramovitz, et al.
Breast Cancer Research and Treatment
|
November 23, 2006
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
Matthew P Goetz, Stacey K Knox, Vera J Suman, et al.
Journal of Medicinal Chemistry
|
November 25, 2024
Discovery of ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα)
Rohan Kalyan Rej, Biao Hu, Zhixiang Chen, et al.
Page
of 13